Veracyte at Jefferies Global Healthcare Conference: Strategic Growth and Innovation

At the Jefferies Global Healthcare Conference 2025, Veracyte (VCYT) highlighted its 2024 performance, including a 28% increase in testing revenue and a 20.6% adjusted EBITDA margin, driven primarily by Afirma and Decipher, which accounted for 95% of total revenue. The company anticipates 14-16% testing revenue growth in 2025 with an improved 22.5% adjusted EBITDA margin, and plans to expand geographically and introduce new products like Prosigna and MRD; however, investors expressed concerns regarding the valuation of the MRD and Prosigna pipelines, which are not yet reflected in the stock price.

Analysis

Veracyte Inc. (VCYT) presented a compelling growth narrative at the Jefferies Global Healthcare Conference 2025, underpinned by strong financial performance and strategic pipeline development. The company reported a significant 28% growth in testing revenue for 2024, achieving a 20.6% adjusted EBITDA margin, primarily driven by its flagship products Afirma and Decipher, which collectively accounted for 95% of total revenue. This momentum continued into Q1 2025 with 18% total revenue growth and 19% testing revenue growth. Veracyte's 2025 guidance anticipates 14% to 16% growth in testing revenue (adjusted for a portfolio decision) and an improved adjusted EBITDA margin of 22.5%, with a long-term target of 25%. Key products show strong market presence, with Decipher holding a 65% market share in prostate cancer prognosis and Afirma a 52% share in thyroid diagnostics, both aiming for over 80% market penetration. Future growth is expected from geographic expansion, particularly in Europe with IVD versions of Decipher and Prosigna, and new product launches including Prosigna as an LDT in the US (mid-2026) and an MRD test for bladder cancer (H1 2026). Despite this robust outlook and a strong cash position of nearly $290 million at year-end 2024, CFO Rebecca Chambers acknowledged investor concerns that the valuation of these pipeline drivers, particularly MRD and Prosigna, is not yet reflected in the stock price. The company's capital allocation strategy remains focused on M&A targets with clear reimbursement paths, maintaining a high bar for acquisitions to ensure they align with Veracyte's profitability profile.

Key Decisions for Investors

• Investors should evaluate Veracyte's current valuation in light of its strong existing product performance and the potential upside from its pipeline, notably Prosigna and MRD, which management believes is currently unpriced by the market.
• Monitor key catalysts including the commercial launch of the MRD test for bladder cancer in H1 2026 and Prosigna LDT in mid-2026, as successful execution and market adoption are critical for realizing future growth projections.
• Consider the competitive landscape, especially in the MRD space where Veracyte is a later entrant, and assess the company's ability to achieve its ambitious market penetration goals against established players, balanced by its strong financial discipline and existing channel strengths.